Index
Introduction
Dear Fellow Shareholders
Our Products
Product Characteristics
Republic of South Africa Approval
Accredited Medical Education Program
Physician Q&A
Phase III Clinical Trials
U.S. Market Opportunity
Medical Readiness
2001 Highlights
Form 10-K
Biopure Corporate Information
Shareholder Information
4. Inventories
Inventories, net of reserves, consisted of the following:
October 31,
2001
2000
In thousands
Raw materials
$
771
$
980
Work-in-process
243
476
Finished goods — Oxyglobin
1,886
1,270
Finished goods — Hemopure
1,765
—
$
4,665
$
2,726
